Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.
Obesity is associated with insulin resistance, non-alcoholic fatty liver disease (NAFLD) and gallstones.High fat diets (unsaturated fats) rich in cholesterol have been demonstrated to produce not only gallstones but also NAFLD and insulin resistance. Interestingly, a high incidence of gallstones is being reported in association with insulin resistance and NAFLD. Laparoscopic cholecystectomy is the best definitive therapy for symptomatic gallbladder disease. Ezetimibe is a drug that inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Importantly, ezetimibe showed potential benefit not only in treating and preventing gallstones but also in insulin resistance and NAFLD. Further studies are required before the use of ezetimibe for the treatment of gallstones can be advocated.
Ahmed
Mohamed H
MH
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D002784:Cholesterol / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004032:Diet; D004353:Drug Evaluation, Preclinical / Q000379:methods; D000069438:Ezetimibe; D005234:Fatty Liver / Q000188:drug therapy; D042882:Gallstones / Q000188:drug therapy*; D006801:Humans; D007333:Insulin Resistance; D007421:Intestine, Small / Q000187:drug effects
D000924:Anticholesteremic Agents; D001384:Azetidines; D002784:Cholesterol; D000069438:Ezetimibe